Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center

Andexanet alfa is approved for the reversal of factor Xa inhibitors in patients with major bleeding events. We aimed to review the incidence of effective hemostasis with andexanet alfa in a real-world environment. This retrospective cohort included patients hospitalized for a major bleed that result...

Descripción completa

Detalles Bibliográficos
Autores principales: Stevens, Victoria M., Trujillo, Toby, Mueller, Scott W., MacLaren, Robert, Reynolds, Paul M., Kiser, Tyree H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019392/
https://www.ncbi.nlm.nih.gov/pubmed/31876159
http://dx.doi.org/10.1177/1076029619896619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019392/
https://www.ncbi.nlm.nih.gov/pubmed/31876159
http://dx.doi.org/10.1177/1076029619896619

Ejemplares similares